MIDDLE EAST & NORTH AFRICA
We supply globally branded pharmaceutical products as well as local brands into multiple territories within MENA. Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2017 financial year.
United Arab Emirates
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The MENA pharmaceutical sector grew 7,9% and was valued at approximately USD29,3 billion for the year to 30 June 2017.
- Growth was largely driven by Algeria and Egypt whose value grew in double digits to USD4,8 billion and USD4,6 billion respectively.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||0,3||0,2||4|
|Other Commercial Pharmaceutical Brands||0,4||0,4||5|
* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.